Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTIV-6: Fluvoxamine (50 mg) in Outpatient COVID-19
NCT05890586Phase 3Completed
- Start
- Jun 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fluvoxamine in coronavirus disease 2019 (COVID-19). Started Jun 2021; status: completed.
02
Drugs
fluvoxamine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05890586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05890586.